Eric Dobmeier
About Eric Dobmeier
Eric Dobmeier is a seasoned director in the biotechnology sector, currently serving at Abdera Therapeutics and ProfoundBio, among others. He has held various leadership roles, including President & CEO at Chinook Therapeutics, and has extensive experience in developing therapeutics and raising significant funds in the industry.
Work at Structure Therapeutics
Eric Dobmeier has been serving as Director at Structure Therapeutics since 2022. In this role, he contributes to the strategic direction and operational management of the organization, focusing on the development of innovative therapeutics. His extensive background in the biotechnology sector supports the company's mission to advance treatments for various diseases.
Current Positions in Biotechnology
In addition to his role at Structure Therapeutics, Eric Dobmeier holds multiple directorial positions in the biotechnology field. He has been a Director at Abdera Therapeutics since 2024, at ProfoundBio since 2023, and at Atara Biotherapeutics since 2015. His diverse roles reflect his commitment to advancing biopharmaceutical innovations.
Previous Experience in Leadership Roles
Eric Dobmeier has held significant leadership positions in various biotechnology companies. He served as President & CEO at Chinook Therapeutics from 2019 to 2023 and at Silverback Therapeutics for 11 months in 2018. His experience also includes a 15-year tenure as Chief Operating Officer at Seagen, where he played a crucial role in the company's growth and development.
Education and Expertise
Eric Dobmeier earned his Juris Doctor (J.D.) from the University of California, Berkeley - School of Law and holds an A.B. in History from Princeton University. His educational background complements his expertise in developing novel therapeutics for cancer, autoimmune, and kidney diseases, positioning him as a knowledgeable leader in the biotechnology sector.
Achievements in Biotechnology Financing
Throughout his career, Eric Dobmeier has demonstrated a strong ability to raise capital within the biotechnology sector. He has successfully raised over $1.5 billion through equity financings and secured $500 million through partnering deals. His financial acumen has significantly contributed to the growth and sustainability of the companies he has worked with.